Bayer backs Iberogast against safety attacks
This article was originally published in OTC Bulletin & The Rose Sheet
Bayer Consumer Health has defended its decision not to include warnings about possible liver-damage when taking its herbal gastrointestinal product Iberogast, after harsh criticism from German Member of Parliament (MP) Kordula Schulz-Asche.
You may also be interested in...
Bayer's Iberogast is in the spotlight in Germany. According to media reports, a German court is investigating a 2018 Iberogast-related death as a possible case of manslaughter and bodily harm caused by negligence. Bayer is standing behind its product, stating that the death was “most probably” due to an “idiosyncratic reaction.”
Sanofi seeks to delay decision clearing path for Mylan's Lantus biosimilar; says it should be able to get rehearing based on Federal Circuit's ruling that PTAB judges were not constitutionally appointed.
First Circuit reverses dismissal of direct purchasers' suit alleging improper listing of patent on device drive mechanism delayed competition; district court to decide if this constitutes antitrust violation.